Clinical Trials Browser

Phase 2 × Completed × glofitamab × Clear all

NCT04703686 2026-03-16

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Phase 2 Completed

Lymphoma, Mantle-Cell